The largest psychiatric safety meta-analysis to date found that GLP-1 medications were not associated with increased risk of serious psychiatric adverse events overall ( Pierret et al., JAMA Psychiatry, 2025 ), and a post-hoc analysis of the major semaglutide weight management trials found no differences in depression, suicidal ideation, or suicidal behavior compared to placebo ( Wadden et al., JAMA Internal Medicine, 2024 )
w Z, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Strov Z, Quintas-Cardama A, Samll D, Cortes J, Andreeff
doi:10.1177/1533317514545379 122
Because Medicare coverage rules have not been formally amended, CMS plans to rely on two demonstration authorities to implement this expansion
Not instant or permanent : Weight loss is gradual, and stopping the medication often leads to weight regain
J., Stine, Z